Tag Archives: PDT

Modulight Spotlights: LASER-SHARP RESEARCH – April 2024

April 10, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – April 2024 First-in-human, phase 1 clinical trial results with ML7710 have been published in a renowned journal Radiology by Timothy Baran and team at University of Rochester Medical Center. The trial investigated treatment of deep tissue abscesses using photodynamic therapy with methylene blue and ML7710 laser. Abscesses are painful collection of pus, usually caused by a bacterial infection. Standard treatment is abscess drainage and antibiotics, however treatment responses vary widely and are linked to prolonged hospital stay, costs, and patient discomfort, as well as increasing concerns for antibiotic-resistance. The trial in 18 Continue reading →

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

March 6, 2024 by Modulight Content
No comments
Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland  Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or Continue reading →

ML7710 for photoactivated treatment of lung cancer

March 6, 2024 by Modulight Content
No comments
Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable patients to stay less time recovering at the hospital. It can also be repeated if needed multiple times without cumulating toxicities, unlike radiation therapy. Some previously inoperable tumors can decrease Continue reading →Deadliest cancer Lung cancer is the leading cause of cancer deaths worldwide, with more than 2.2 million cases and 1.8 million deaths each year [1]. Lung cancer can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 85% of all lung cancer cases. NSCL is usually less sensitive to chemo- and radiotherapy and in many cases tumor cannot be removed surgically or has spread from lungs to distant sites at the time Continue reading →

Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

September 6, 2023 by Modulight Content
No comments
Published in: Science Advances Authors: Barry J. Liang(1,2), Sumiao Pang(1), Robert Perttilä(3), Chen-Hua Ma(1), Payal Srivastava(1), Brandon Gaitan(1), Aaron J. Sorrin (1), Nada Fadul(1), Zoe Ylöniemi(3), Dana M. Roque(4,5), Tayyaba Hasan(6), Petteri Uusimaa(3), Huang-Chiao Huang(1,4*) (1) Fischell Department of Bioengineering, University of Maryland (2) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (3) Modulight Corp., Finland (4) Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine (5) Department of Obstetrics, Gynecology and Reproductive Sciences, University Continue reading →Published in: Science Advances Authors: Barry J. Liang(1,2), Sumiao Pang(1), Robert Perttilä(3), Chen-Hua Ma(1), Payal Srivastava(1), Brandon Gaitan(1), Aaron J. Sorrin (1), Nada Fadul(1), Zoe Ylöniemi(3), Dana M. Roque(4,5), Tayyaba Hasan(6), Petteri Uusimaa(3), Huang-Chiao Huang(1,4*) (1) Fischell Department of Bioengineering, University of Maryland (2) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (3) Modulight Corp., Finland (4) Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine (5) Department of Obstetrics, Gynecology and Reproductive Sciences, University Continue reading →

Photodynamic Therapy of an Abdominal Abscess at the Time of Percutaneous Drainage

July 18, 2023 by Modulight Content
No comments
Published in: Cardiovascular and Interventional Radiology Authors: Timothy M. Baran, Ashwani Kumar Sharma    Published in: Cardiovascular and Interventional Radiology Authors: Timothy M. Baran, Ashwani Kumar Sharma   This article presents a successful case study from an ongoing Phase 1 clinical trial where methylene blue together with ML7710 is used to eradicate bacteria and biofilm in the treatment of persistent abscesses. The potential of Photodynamic Therapy (PDT) is explored as an adjunct treatment for recurrent or challenging-to-manage abdominal abscesses during percutaneous drainage procedures. Despite advancements in abscess drainage techniques and antibiotics, some cases exhibit low response rates and recurrences, Continue reading →

Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy

June 26, 2023 by Modulight Content
No comments
Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang    Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang   The study showed that fluid flow induced shear stress increased the photocytotoxicity of different photosensitizers tested (BPD, PIC, PIC-coated liposome) against ovarian cancer cells. The cellular delivery of photosensitizers doubled compared to static conditions. Modulight laser was used for PDT activation together with photosensitizer(s). Circulating drugs in the peritoneal cavity is an effective strategy for advanced ovarian Continue reading →

Fluorescence-guided, targeted photochemotherapy of peritoneal carcinomatosis

March 17, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Barry J. Liang, Robert Perttilä, Sumiao Pang, Chen-Hua Ma, Payal Srivastava, Brandon Gaitan, Aaron J. Sorrin, Zoe Ylöniemi, Dana Roque, Tayyaba Hasan, Petteri Uusimaa, Huang-Chiao Huang    Presented in: SPIE BIOS 2023 Authors: Barry J. Liang, Robert Perttilä, Sumiao Pang, Chen-Hua Ma, Payal Srivastava, Brandon Gaitan, Aaron J. Sorrin, Zoe Ylöniemi, Dana Roque, Tayyaba Hasan, Petteri Uusimaa, Huang-Chiao Huang   Management of peritoneally metastatic cancer is a major clinical challenge. Peritoneal carcinomatosis is observed in 50% of colorectal cancer patients and >75% of ovarian cancer patients at the time of diagnosis. Selected patients based on age, comorbidities, and extent of the metastatic disease, will undergo complete cytoreductive surgery to remove the visible Continue reading →

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.   Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light Continue reading →

Novel ophthalmic PDT laser platform to target oncology and various other retinal indications

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.   Laser systems, in ophthalmic applications, are utilized in the treatment of various ophthalmic diseases such as in ocular oncology and age-related macular degeneration through photochemical mechanism of photodynamic therapy. In addition, these lasers can be used to activate drug delivery systems in the retina to provide targeted drug therapy. PDT is a form of a combination treatment which utilizes light energy to Continue reading →

Optimization of light delivery for non-muscle invasive bladder cancer PDT

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Elias Kokko, Robert Perttilä, Zoe Ylöniemi, Visa Kaivosoja, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Elias Kokko, Robert Perttilä, Zoe Ylöniemi, Visa Kaivosoja, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.   Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light sources and Continue reading →